IDC2503 (atezolizumab biosimilar)
/ Prestige BioPharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 05, 2025
Cabozantinib/Atezolizumab Improves PFS in Patients With mCRPC and Extrapelvic Metastases
(Targeted Oncology)
- "'Patients with mCRPC whose disease has progressed on ARPI have a poor prognosis, with relatively short overall survival,' wrote Neeraj Agarwal, MD, and colleagues."
Media quote
1 to 1
Of
1
Go to page
1